Business Context and Reporting Period
Xilio Therapeutics, Inc. (XLO) filed a Form 8-K on February 10, 2025, reporting the entry into a material definitive agreement with AbbVie Group Holdings Limited. The Company, an emerging growth company focused on tumor-activation technology, entered into a collaboration, license, and option agreement covering up to four programs involving masked T cell engager molecules and masked antibody-based immunotherapies.
Key Financial Metrics and Transaction Details
The transaction includes significant upfront financial consideration and potential future contingent payments:
- Upfront Payments: Total of $52.0 million, comprising a $42.0 million cash payment and a $10.0 million equity investment.
- Equity Investment: AbbVie purchased 4,347,826 shares of Xilio common stock at $2.30 per share in a private placement closed on February 11, 2025.
- Contingent Payments: Eligibility for up to approximately $2.1 billion in additional payments, including up to $305.0 million in program nomination and option fees, and up to $1.8 billion in development, regulatory, and sales-based milestones.
- Royalties: Tiered royalties in the high single digits for Option Programs and mid single digits for the Collaboration Program on annual global net product sales.
Material Changes and Program Structure
The agreement establishes a multi-tiered development structure:
- Option Programs: AbbVie holds an exclusive option for an initial program and up to two additional programs to discover, develop, and commercialize masked T cell engager molecules. Xilio is responsible for preclinical discovery up to IND-enabling studies, while AbbVie assumes responsibility for clinical development and commercialization upon option exercise.
- Collaboration Program: AbbVie received an exclusive global license for a masked antibody-based immunotherapy program. Xilio handles preclinical development through lead generation, with AbbVie managing subsequent development and commercialization.
- Exclusivity: Xilio has agreed to work exclusively with AbbVie regarding the targets for the Option and Collaboration Programs.
Guidance, Outlook, and Risks
Liquidity Outlook: Management anticipates that existing cash and cash equivalents, combined with the $52.0 million upfront proceeds, will be sufficient to fund operating expenses and capital expenditures into the first quarter of 2026.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers regarding market conditions, the receipt of contingent future payments, and the sufficiency of cash to fund operations. The agreement allows AbbVie to terminate for convenience or if option extension fees are not paid, which could result in the automatic termination of specific Option Programs.
Investor Verification Checklist
- Verify the closing of the $10.0 million private placement and the issuance of 4,347,826 shares to AbbVie.
- Confirm the receipt of the $42.0 million cash upfront payment.
- Review the specific targets selected for the Initial Option Program and any Additional Option Programs.
- Monitor the timeline for preclinical discovery milestones required to trigger option extension fees.
- Assess the impact of the equity issuance on existing shareholder dilution.